In vitro proteotoxic synergism of nelfinavir and carfilzomib in solid cancer cell lines
Jan 1, 2013
HER2-positive breast cancer accounts for approximately 25-30% of all breast cancer cases, and carries a bad prognosis compared to HER2-negative breast cancer. Despite recent advances with the development of HER2-targeted treatments, mainly trastuzuma...
Fundamental Research -
Jan 1, 2013 - Dec 31, 2014
Automatically Closed
Members: Driessen Christoph, Gibbons-Marsico Jennifer, Kraus Marianne
more
